Home Family Practice FDA Approves Linzess to Treat Constipation in Children, Teens

FDA Approves Linzess to Treat Constipation in Children, Teens

Linzess now approved for functional constipation in pediatric patients ages 6 to 17 years

By Lori Solomon HealthDay Reporter

WEDNESDAY, June 14, 2023 (HealthDay News) — The U.S. Food and Drug Administration approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation.

The approval was based on data from 328 participants who were randomly assigned (1:1) to receive Linzess or placebo. A statistically significant benefit and clinically meaningful improvement was seen for 12-week spontaneous bowel movement frequency rate with Linzess compared with placebo, with Linzess-treated patients showing a greater than twofold least squares mean change from baseline in spontaneous bowel movements per week (2.6 versus 1.3). Diarrhea was the most common adverse event reported (4 percent of Linzess-treated patients versus 2 percent of placebo-treated patients).

“Pediatric functional constipation is an all-too-common issue that physicians see every day, yet despite the tremendous distress it causes to our patients and their families, we haven’t had an FDA-approved prescription treatment to offer until now,” Jeffrey S. Hyams, M.D., from the Connecticut Children’s Medical Center and the University of Connecticut in Hartford, said in a statement. “The approval of Linzess for the treatment of functional constipation in pediatric patients ages 6 to 17 years old is a meaningful advancement for these young patients.”

Expanded approval of Linzess was granted to Ironwood Pharmaceuticals.

Copyright © 2023 HealthDay. All rights reserved.